ArticleCancer diagnosis & prognosis

Long-term Progression-free Survival With Pemetrexed Plus Bevacizumab in NSCLC Patients.

Shigen Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.